Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported;

返回会议原文

返回会议

MedShr· @medshronline · X·2026-10-24 23:15· 13 小时前评分70

NATALEE

正文 · 机器翻译

在#ESMO2026公布的六年期NATALEE数据：辅助治疗ribociclib联合NSAI，与单用内分泌治疗相比，将HR+/HER2−早期乳腺癌患者的死亡风险降低了19%。数据由公司报告；完整论文尚待发表。

#BreastCancer #Oncology #MedTwitter

63 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

来源：MedShr · x.com